Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in Amyotrophic Lateral Sclerosis

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 84, Issue 4, 2013, Pages 467-472

  Boylan, Kevin B ^a   Glass, Jonathan D ^b   Crook, Julia E ^a   Yang, Cui ^c   Thomas, Colleen S ^a   Desaro, Pamela ^a   Johnston, Amelia ^a   Overstreet, Karen ^a   Kelly, Crystal ^b   Polak, Meraida ^b   Shaw, Gerry ^c  

^a MAYO CLINIC   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; NEUROFILAMENT PROTEIN; PROTEIN PNF H; RILUZOLE; UNCLASSIFIED DRUG;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; AMYOTROPHIC LATERAL SCLEROSIS FUNCTIONAL RATING SCALE; ARTICLE; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MALE; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RATING SCALE; SURVIVAL;

EID: 84875225946     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2012-303768     Document Type: Article

References (19)

1. Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet 2011;12:377:942-55.
2. Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol 2011;7:639-49.
3. Chio A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 2009;10:310-23.
4. Traynor BJ, Zhang H, Shefner JM, on behalf of the NC. Functional outcome measures as clinical trial endpoints in ALS. Neurology 2004;63:1933-5. (Pubitemid 39532394)
5. Bowser R, Turner MR, Shefner J. Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations. Nat Rev Neurol 2011;7:631-8.
6. Turner MR, Kiernan MC, Leigh PN, et al. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol 2009;8:94-109.
7. Boylan K, Yang C, Crook J, et al. Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker. J Neurochem 2009;111:1182-91.
8. Brettschneider J, Petzold A, Sussmuth SD, et al. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 2006;66:852-6. (Pubitemid 43739759)
9. Ganesalingam J, An J, Shaw CE, et al. Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem 2011;117:528-37.
10. Tortelli R, Ruggieri M, Cortese R, et al. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol Published Online First: 11 June 2012. doi: 10.1111/j.1468-1331.2012.03777.x
11. Zetterberg H, Jacobsson J, Rosengren L, et al. Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. Eur J Neurol 2007;14:1329-33. (Pubitemid 350135296)
12. Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999;169:13-21. (Pubitemid 29502501)
13. Miller RG, Moore DH II, Gelinas DF, et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001;56:843-8. (Pubitemid 32293584)
14. Dejesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72:245-56.
15. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314:130-3. (Pubitemid 44547757)
16. Renton AE, Majounie E, Waite A, et al. A Hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72:257-68.
17. Brettschneider J, Petzold A, Sussmuth SD, et al. Neurofilament heavy-chain NfH (SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes. Mov Disord 2006;21:2224-7. (Pubitemid 46140444)
18. Guy J, Shaw G, Ross-Cisneros FN, et al. Phosphorylated neurofilament heavy chain is a marker of neurodegeneration in Leber hereditary optic neuropathy (LHON). Mol Vis 2008;14:2443-50.
19. Kuhle J, Regeniter A, Leppert D, et al. A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. J Neuroimmunology 2010;220:114-19.